← Back to Search

Oxygen Carrier

Hemopure for Anemia

N/A
Waitlist Available
Led By Carmine Gianatiempo, MD
Research Sponsored by Englewood Hospital and Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 week
Awards & highlights
No Placebo-Only Group

Summary

This trial will allow people with life-threatening anemia to be treated with HBOC-201, which is not FDA approved in the US, but is approved as an oxygen carrier in South Africa and Russia.

Eligible Conditions
  • Anemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 week
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 week for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
survival

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: All subjectsExperimental Treatment1 Intervention
all qualifying subjects will receive HBOC-201 (Hemopure) to treat their life-threatening anemia

Find a Location

Who is running the clinical trial?

Englewood Hospital and Medical CenterLead Sponsor
20 Previous Clinical Trials
723 Total Patients Enrolled
HbO2 Therapeutics LLCIndustry Sponsor
2 Previous Clinical Trials
2 Trials studying Anemia
Carmine Gianatiempo, MDPrincipal InvestigatorEnglewood Hospital and Medical Center
1 Previous Clinical Trials
19 Total Patients Enrolled

Media Library

HBOC-201 (Oxygen Carrier) Clinical Trial Eligibility Overview. Trial Name: NCT01881503 — N/A
Anemia Clinical Trial 2023: HBOC-201 Highlights & Side Effects. Trial Name: NCT01881503 — N/A
HBOC-201 (Oxygen Carrier) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01881503 — N/A
~4 spots leftby Dec 2025